Celyad R&D Day Highlights Nextgen, Off-Shelf Non-gene Edited CAR-T Candidates

shRNA platform complements Company’s all-in-one-vector approach in the design, discovery and development of next-generation CAR-T candidates

* Allogeneic T-cells derived by shRNA targeting show distinctive profile compared to CRISPR-Cas9 gene edited cells in preclinical assays

* Plans to initiate several Phase 1 trials to evaluate lead candidates, including next generation, autologous NKG2D-based CYAD-02 and three first-in-class, shRNA-based, non-gene edited allogeneic CAR-T therapies from the CYAD-200 series

https://www.marketscreener.com/CELYAD-13479209/news/Celyad-Celyad-s-2019-R-D-Day-Highlights-shRNA-Platform-and-Pipeline-of-Next-generation-NKG2D-b-28191090/